



European Journal of Histochemistry

SUPPLEMENTARY MATERIAL

DOI: [10.4081/ejh.2020.3264](https://doi.org/10.4081/ejh.2020.3264)

Identification of abnormally high expression of *POGZ* as a new biomarker associated with a poor prognosis in osteosarcoma

Sikuan Zheng,^{1,2,3,4*} Yue Liu,^{5*} Haohe Sun,² Jingyu Jia,^{1,3,4} Tianlong Wu,^{1,3,4} Rui Ding,^{1,2,3,4}
Xigao Cheng^{1,3,4}

¹The Second Affiliated Hospital of Nanchang University, Jiangxi

²The Second Clinical Medical College of Nanchang University, Jiangxi

³Institute of Orthopedics of Jiangxi Province, Nanchang, Jiangxi


⁴Institute of Minimally Invasive Orthopedics of Nanchang University, Jiangxi

⁵Queen Mary School, Medical College of Nanchang University, Nanchang, Jiangxi, China

*These authors contributed equally.


Correspondence: Prof. Xigao Cheng, The Second Affiliated Hospital of Nanchang University, No.1 Minde Road, EastLaker District, Nanchang, Jiangxi, China. Tel. +86.791.8633-1753. E-mail: 228206846@qq.com

Key words: Prognosis; osteosarcoma; biomarkers; *POGZ*; cell cycle.




Supplementary Figure 1.

Screening data set flowchart. We screened out 281 data sets by searching keywords in GEO Datasets and eliminated 244 cell line studies and 31 non-conforming studies based on the inclusion and exclusion criteria, and finally included 6 data sets.




Supplementary Figure 2.

The Kaplan-Meier survival curve of TARGET_OS dataset shows that HR=2.06(0.93~4.59) and p=0.07. The result indicates that high expression of POGZ is a risk factor for OS.




Supplementary Figure 3.

The Kaplan-Meier survival curve of GSE39055 dataset shows that HR=1.4(0.55~3.54) and p=0.5. The result indicates that high expression of POGZ is a risk factor for OS.




Supplementary Figure 4.

Forest plot of *POGZ* expression across three datasets (GSE21257, GSE39055 and TARGET_OS). The results showed that *POGZ* was steadily upregulated without heterogeneity ($I^2 = 0\%$, $Z = 2.66$, $p=0.008$).




Supplementary Figure 5.

The forest map of *POGZ* expression level analysis for the metastatic and non-metastatic group of six data sets. The results have big heterogeneity.



Supplementary Figure 6.

The relationship between *POGZ* expression and the prognosis of multiple tumors. Compared with the *POGZ* low expression group, the *POGZ* high expression group had a shorter disease-free survival time and a poor prognosis (disease-free survival rate $HR = 0.91$, $p=0.017$).



Supplementary Figure 7.

The relationship between *POGZ* expression and the prognosis of multiple tumors. The results indicate that high expression of *POGZ* is a specific risk factor for overall survival (OS rate HR = 0.9, $p=0.0065$).